FDA recalls endoscope cleaning devices due to infection risk

The Food and Drug Administration has ordered the recall of roughly 2,800 Custom Ultrasonics automated endoscope reprocessors (AERs) from hospitals and other healthcare facilities, claiming the company cannot prove that the devices properly clean and disinfect endoscopes.

The Warminster, Pennsylvnia-basedcompany "has a history of violating federal rules for manufacturing and quality control," the AP reported. The FDA ordered the recall under a 2007 consent decree with Custom Ultrasonics.

The recall is "necessary to protect the public health," William Maisel, the FDA's deputy director for medical devices, said in the agency's recall announcement.

It was unclear whether any of Custom Ultrasonics' AERs were part of a superbug outbreak that killed and sickened patients in hospitals nationwide after they underwent endoscopic procedures. The drug-resistant bacteria Carbapenem-resistant Enterobacteriaceae (CRE) was passed from patient to patient; CRE infections in the bloodstream have a 50 percent fatality rate.

The FDA warned at the time that duodenocope manufacturers' sterilization protocols might be inadequate, as FierceHealthcare reported, and later issued new guidelines.

Last week ECRI Institute named inadequate cleaning of devices as the top health hazard for 2016

To learn more:
- here's the FDA's announcement
- read the AP report via ABC News

Related Articles:
FDA issues warning about scopes linked to superbug outbreak
CDC urges hospital action to stop deadly bacteria
FDA advisory panel: Superbug-linked scopes put patients in danger
FDA tells scope cleaners to ramp up testing; cites one manufacturer
Appliances used to clean superbug-linked scopes may be flawed
Inadequate device cleaning tops alarm fatigue on ECRI health hazards list 

 

 

Suggested Articles

Blue Cross and Blue Shield of North Carolina and Cambia Health Solutions have jointly decided to end their talks to enter a "strategic affiliation."

California health officials have released their first report on the price hikes drug companies sought to shield.

Here is a rundown of major regulations and legislation to expect for the rest of 2019, from the Stark Law to drug prices.